# US 2001/0027199 A1 · Use of certain drugs for treating nerve root injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027199 A1
- Document ID: US20010027199A1
- Status: Published application
- Kind: A1
- Application number: 09/760,810
- Filed: 2001-01-17
- Published: 2001-10-04
- Earliest claimed: 1998-09-25
- Assignees: A+ Science AB (publ)
- Inventors: Kjell Olmarker; Bjorn Rydevik
- Web page: https://patentgrep.com/patent/US20010027199A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/33: Heterocyclic compounds
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/65: Tetracyclines
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/02: without antiinflammatory effect
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well as a method for treatment of such disorders, and the use of TNF-α inhibitors in the preparation of pharmaceutical compositions for such treatment.

## Claims

### Claim 1

A method of treating a nerve disorder in a mammal in need of such treatment comprising the step of administering a TNF-α inhibitor selected from the group consisting of: (a) metalloproteinase inhibitors excluding methylprenisolone, (b) quinolones, (c) corticosteroids, (d) thalidomide, (e) lazaroides, (f) pentoxyphyllines, (g) hydroxamic acid derivatives, (h) carbocyclic acids, (i) napthopyrans, (j) amrinone, (k) pimobendan, (1) vesnarinone, (m) phosphodiesterase III inhibitors, (n) lactoferrin and lactoferrin derived analogs, (o) melatonin, and bases or addition salts thereof, for the treatment of nerve disorders in said mammal in need of such treatment wherein said nerve disorder is caused by the liberation of TNF-α and compounds triggered by the liberation of or presence of TNF-α by inhibiting TNF-α.

### Claim 2

A pharmaceutical composition for the treatment of a nerve disorder in a mammal in need of such treatment comprising a pharmaceutically effective amount of a TNF-α inhibitor selected from the group consisting of: (a) metalloproteinase inhibitors excluding methylprenisolone, (b) quinolones, (c) corticosteroids, (d) thalidomide, (e) lazaroides, (f) pentoxyphyllines, (g) hydroxamic acid derivatives, (h) carbocyclic acids, (i) napthopyrans, (j) amrinone, (k) pimobendan, (l) vesnarinone, (m) phosphodiesterase III inhibitors, (n) lactoferrin and lactoferrin derived analogs, (o) melatonin, and bases or addition salts thereof, and a pharmaceutically acceptable carrier for the treatment of nerve disorders in said mammal in need of such treatment wherein said nerve disorder is caused by the liberation of TNF-α and compounds triggered by the liberation of or presence of TNF-α by inhibiting TNF-α.
